



Sage Therapeutics to Present at Leerink Partners 7th Annual Global Healthcare Conference

February 12, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 12, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a fireside chat presentation at the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 1:30 P.M. ET in New York.

A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed two Phase 3 clinical trials in postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180212005766/en/>

Source: Sage Therapeutics

Sage Therapeutics

Investor:

Paul Cox, 617-299-8377

paul.cox@sagerx.com

or

Media:

Maureen L. Suda, 585-355-1134

maureen.suda@sagerx.com